|
Antonio Brú Espino (born 1962) is Theoretical physicist and permanent professor in the Departament of Applied Mathematics at the Universidad Complutense de Madrid.〔(Antonio Brú, Ph.D. | Center for the Development of a Virtual Tumor )〕 Brú received his PhD in 1995 from the Universidad Complutense de Madrid, in physics, with advisor Miguel Ángel Rodríguez. He began his research career in 1989 at the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) in the field of anomalous transport and complex systems. In 1993, he established his own research group to study tumor growth. In 2002, he moved to the Consejo Superior de Investigaciones Científicas(CSIC). ==Cancer research== Brú is known for the controversy surrounding his research on cancer, which states (among other things) that: * The defining factor that determines the growth of solid tumours is not the search for nutrients, but the search for space to grow. * Solid tumours may be treated solely through an enhancement of the immune response, achievable with high doses of Neupogen, a granulocyte colony-stimulating factor (G-CSF) routinely used in Oncology in order to recover the level of these blood cells after Chemotherapy. Brú's theory stems from his mathematical research on the Fractal growth of tumour cell colonies ''in vitro''. This growth, according to his studies, would display a set of distinct characteristics with regards to growth patterns and would imply a greater proliferation around tumour boundaries. Brú's team referred this growth pattern as the ''Universal Dynamics of Tumour Growth''. This theory is currently recognised as one of the possible equations to describe tumour growth. The rationale for the use of Neupogen would be that the concurrence of a massive amount of neutrophils near the edge of the tumour may result in a massive population in the concavities at the tumour edge, consequently blocking its growth. He has published his research in Europhysics Letters (2003),〔(Anomalous scaling of multivalued interfaces )〕 the Biophysical Journal (2003) (where he expands on the MBE theory), and in Physical Review Letters (2004). Brú reported treating two patients with G-CSF: a male with terminal hepatic cancer and a female with a Phase IV Melanoma. He published the tumour remission of the hepatocellular carcinoma patient in the Journal of Clinical Research (May 2005) 8: 9-13.,〔(Journal of Clinical Research - efficacy of new clinical interventions )〕 a source of controversy, as the publication has no impact factor. His alleged success on the two patients, the fact that Brú comes from the Complutense University, his collaboration with researchers from the Spanish Scientific Research Council CSIC and the San Carlos Hospital in Madrid, as well as the mix of mathematical and biological research, made his theory a breaking news event in Spain. Brú has publicly asked for the possibility of doing clinical trials in order to confirm his results, but this has been impossible to date. It was nearly done in the Ramón y Cajal hospital〔(Hospital Ramon Cajal )〕 in Madrid, but there was no consensus due to conditions deemed unacceptable by Brú's team: * A statistically insignificant number of patients; * The addition of a mortality case in the information given for patient consent of which Brú had no knowledge of. * The animosity from a potential team member. In June 2007 Brú presented a new proposal for a clinical trial to the ''Fundación Puigvert'' 〔(intro )〕 in Barcelona for Prostate cancer,〔http://www.mat.ucm.es/~abruespi/〕 but it was rejected by said Foundation. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Antonio Brú」の詳細全文を読む スポンサード リンク
|